Singapore, May 18 -- ImmunityBio, Inc., a commercial-stage immunotherapy company, has announced an exclusive US Development and Supply Agreement with Japan BCG Laboratory (JBL), the Tokyo-based developer and manufacturer of the Tokyo strain of BCG (Tokyo-172 BCG). The agreement provides ImmunityBio exclusive US rights to develop, import, and commercialise intravesical Tokyo-172 BCG.

JBL's Tokyo strain of BCG is supported by the February 2026 positive Phase III readout of SWOG S1602, a randomised Phase III study sponsored by the National Cancer Institute (NCI), which demonstrated non-inferiority of the Tokyo strain of BCG to TICE BCG in BCG-naive high-grade non-muscle invasive bladder cancer (NMIBC).

The pre-specified non-inferiority mar...